Ajanta Pharmaceuticals financials

·Pharma & HealthChart ›
Latest results Q1 FY27 · Apr–Jun 2026
Revenue
₹1,626cr+24.8% on Q1 FY26
Net profit
₹334cr+30.9% on Q1 FY26
EBITDA margin
26.1%−0.9 pts on Q1 FY26
EPS
₹26.75+30.9% on Q1 FY26

Quarterly results

Every quarter ›
₹ croreQ1 FY27Q1 FY26Change
Revenue1,6261,303+24.8%
EBITDA424351+20.6%
EBITDA margin26.1%27.0%−0.9 pts
Profit before tax447331+34.9%
Net profit334255+30.9%
EPS₹26.75₹20.44+30.9%

Over time

Q1 FY27 · Apr–Jun 2026latest
Revenue₹1,626 crNet profit₹334 crNet margin20.6%

Amounts on the left scale in ₹ crore; per cent on the right, dashed. L = lakh crore, K = thousand crore. Touch the chart to read any period.

Key numbersby financial year

₹ crore except per share
Tap a line for its trendCurrentlast 12MFY26Mar 2026FY25Mar 2025FY24Mar 2024FY23Mar 2023FY22 and earlierAlpha Plus
43,369————
FY22 and earlierEvery year the company has filed comes with Alpha Plus.
663663614460840
2122122.61.51.4
42,917————
5,7765,4534,6484,2093,743
—+17.3%+10.4%+12.5%—
1,4671,3951,2601,172783
25.4%25.6%27.1%27.9%20.9%
1,2911,2221,1151,037652
1,1351,056920816588
19.6%19.4%19.8%19.4%15.7%
₹90.20₹84.24₹73.43₹65.18₹46.91
—+14.7%+12.7%+38.9%—
—5291,157785792
—−365−318−152−174
164164839633617
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

AJANTPHARM₹3,459.80

Ajanta Pharmaceuticals Ltd.

· Pharma & Health
₹ CrorePeersALKEMIPCALABTORNTPHARMABBOTINDIAANTHEMGLAXOMEDANTAGLENMARKMcap ₹43,369 Cr
HighlightsEnterprise ValueMultiplesPer ShareAnnuals · FY-end closes
In ₹ Crore except Per Share
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Current/LTM
TTM · last close
Market Capitalization————43,368.6
- Cash, Equiv & ST Investments840.1459.5613.8663.1663.1
+ Total Debt1.41.52.6212.0212.0
Enterprise Value————42,917.5
Revenue3,742.64,208.74,648.15,452.95,776.2
Growth %, YoY—+12.5+10.4+17.3—
EBITDA783.31,171.91,259.51,394.81,467.1
Margin %20.9327.8527.1025.5825.40
EBIT652.51,036.51,115.41,221.71,290.7
Net Income588.0816.2920.41,056.01,134.9
Margin %15.7119.3919.8019.3719.65
EPS, Adj (current shares)46.9165.1873.4384.2490.20
Growth %, YoY—+38.9+12.7+14.7—
Cash from Operations791.8785.11,157.2529.2—
Capital Expenditures-174.5-152.4-317.9-365.2—
Free Cash Flow617.3632.7839.3164.0164.0
Market Cap/EV/multiples pair each (split/bonus-adjusted) FY-end close with the latest filed share count; Current column uses the last close. Market Capitalization is a market-level figure — identical across Consolidated/Standalone (the accounting rows below differ). No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.

Ajanta Pharmaceuticals financials and key ratios

Prices at the 29 October 2026 close · figures from the company's filings with NSE

Ajanta Pharmaceuticals (NSE: AJANTPHARM) had a market capitalisation of ₹43,367 crore at the 29 October 2026 close (₹3,459.70 a share), a PE ratio of 38.4 on the last four quarters' profit and a price-to-book ratio of 9.58. In FY26 its consolidated net profit attributable to shareholders was ₹1,056 crore on revenue of ₹5,453 crore; in Q1 FY27 (April–June 2026) it was ₹330 crore, up 29.2% year on year. Its debt-to-equity ratio was 0.05 on 31 March 2026. Promoters held 63.47% of the shares on 30 September 2026.

Share price used
₹3,459.70 · 29 October 2026 close
Latest balance sheet
31 March 2026
Shareholding pattern
30 September 2026

Ajanta Pharmaceuticals at a glance · consolidated

Market cap
₹43,367 Crat ₹3,459.70 · 29 Oct close
PE ratio (last 4 quarters)
38.441.1 on FY26 profit
Price to book (PB)
9.58book value ₹361.16 a share
ROE (FY26)
25.4%+0.4 pts vs FY25ROCE 27.9%
Debt to equity
0.05net cash ₹453 Cr
Promoter holding
63.47%unchanged vs 30 Jun 202630 September 2026
Dividend yield
1.73%₹60 a share in 12 months
Net worth
₹4,527 Cr+19.4% vs 31 Mar 202531 March 2026
Free cash flow (FY26)
₹164 Cr−80.5% vs FY25

Questions

What is the Ajanta Pharmaceuticals PE ratio today?

Ajanta Pharmaceuticals' PE ratio is 38.4 at the 29 October 2026 close (₹3,459.70 a share): a market capitalisation of ₹43,367 crore divided by consolidated net profit attributable to shareholders of ₹1,131 crore over the last four quarters (Q2 FY26 to Q1 FY27). On FY26 net profit attributable to shareholders (₹1,056 crore) it is 41.1.

What is the Ajanta Pharmaceuticals PB ratio (price to book value)?

Ajanta Pharmaceuticals' price-to-book (PB) ratio is 9.58 at the 29 October 2026 close: a market capitalisation of ₹43,367 crore divided by shareholders' equity (book value) of ₹4,527 crore on 31 March 2026. That is a book value of ₹361.16 per share against a share price of ₹3,459.70.

What is the Ajanta Pharmaceuticals ROE and ROCE?

In FY26, Ajanta Pharmaceuticals' return on equity (ROE) was 25.4% and its return on capital employed (ROCE) was 27.9%. ROE is net profit attributable to shareholders divided by average shareholders' equity (the start and end of the year); ROCE is operating profit (EBIT) divided by average capital employed (total assets less current liabilities). In FY25, ROE was 25.0% and ROCE 28.7%.

What is the Ajanta Pharmaceuticals market cap?

Ajanta Pharmaceuticals' market capitalisation was ₹43,367 crore at the 29 October 2026 close: 12.54 crore shares at ₹3,459.70 each.

Is Ajanta Pharmaceuticals debt free?

No. Ajanta Pharmaceuticals had borrowings of ₹212 crore on 31 March 2026 (consolidated balance sheet), a debt-to-equity ratio of 0.05. Its cash and current investments were ₹665 crore, so it held net cash of ₹453 crore.

What is the Ajanta Pharmaceuticals dividend in 2026 and its record date?

In 2026, Ajanta Pharmaceuticals has declared one dividend: ₹32 (interim) with record date 5 August 2026.

What is the Ajanta Pharmaceuticals debt to equity ratio?

Ajanta Pharmaceuticals' debt-to-equity ratio was 0.05 on 31 March 2026: borrowings of ₹212 crore against total equity of ₹4,527 crore. A year earlier, on 31 March 2025, it was 0.00.

What is the Ajanta Pharmaceuticals net worth?

Ajanta Pharmaceuticals' net worth — shareholders' equity in its consolidated balance sheet — was ₹4,527 crore on 31 March 2026, up 19.4% from ₹3,790 crore a year earlier. Its market value is a different figure: a market capitalisation of ₹43,367 crore at the 29 October 2026 close.

What is the Ajanta Pharmaceuticals book value per share?

Ajanta Pharmaceuticals' book value per share was ₹361.16 on 31 March 2026: shareholders' equity of ₹4,527 crore divided by the 12.54 crore shares in issue, up 19.4% from ₹302.38 a year earlier. The share price at the 29 October 2026 close was ₹3,459.70.

What is the Ajanta Pharmaceuticals EPS?

Ajanta Pharmaceuticals' basic earnings per share (EPS) were ₹84.53 in FY26, against ₹73.56 in FY25. Over the last four quarters (Q2 FY26 to Q1 FY27) they add up to ₹90.84.

What is the Ajanta Pharmaceuticals promoter holding?

Promoters held 63.47% of Ajanta Pharmaceuticals on 30 September 2026, down 0.01 percentage points from 63.48% the previous quarter and down 2.78 percentage points from 66.25% a year earlier, according to the shareholding pattern filed with NSE.

When are the Ajanta Pharmaceuticals next results?

Ajanta Pharmaceuticals will announce its Q2 FY27 results (July–September 2026) on Friday, 30 October 2026, the date of the board meeting it has notified to the exchanges.

What is the Ajanta Pharmaceuticals dividend yield?

Ajanta Pharmaceuticals' dividend yield is 1.73% at the 29 October 2026 close: dividends of ₹60 a share that went ex-dividend in the 12 months before that day, divided by the share price of ₹3,459.70. They were ₹32 on 5 August 2026 (interim) and ₹28 on 10 November 2025 (interim).

What is the Ajanta Pharmaceuticals shareholding pattern?

On 30 September 2026, Ajanta Pharmaceuticals' shares were held by promoters 63.47%, foreign portfolio investors (FII/FPI) 7.63%, domestic institutions (DII) 21.94% (including mutual funds at 17.95%) and retail and other non-institutional investors 6.96%. Over the year, FII holding was down 0.90 percentage points from 8.53% and DII holding was up 4.04 percentage points from 17.90%.

What is the Ajanta Pharmaceuticals free cash flow?

In FY26, Ajanta Pharmaceuticals generated ₹529 crore of cash from operations and spent ₹365 crore on capital expenditure (property, plant, equipment and intangibles), leaving free cash flow of ₹164 crore. In FY25 it was ₹839 crore.

What are the Ajanta Pharmaceuticals latest quarterly results?

Ajanta Pharmaceuticals' latest results are for Q1 FY27 (April–June 2026), filed on 30 July 2026: consolidated net profit attributable to shareholders ₹330 crore, up 29.2% from ₹255 crore in Q1 FY26; revenue from operations ₹1,626 crore, up 24.8% year on year.

What is the Ajanta Pharmaceuticals revenue and profit in FY26?

In FY26 (April 2025–March 2026), Ajanta Pharmaceuticals' consolidated net profit attributable to shareholders was ₹1,056 crore, up 14.7% from ₹920 crore in FY25, on revenue from operations of ₹5,453 crore (up 17.3%). Over three years, from FY23, net profit was up 79.6%.

How does the Ajanta Pharmaceuticals PE ratio compare with its peers?

At the 29 October 2026 closing prices, on FY26 net profit attributable to shareholders, Ajanta Pharmaceuticals' PE ratio is 41.1, the third highest of the four: Alkem Laboratories 26.4, Ipca Laboratories 42.8 and Torrent Pharma 80.5, a peer average of 49.9. Each is the company's market capitalisation at that price divided by its FY26 net profit.

How does Ajanta Pharmaceuticals compare with its peers?

On FY26 consolidated figures, against Alkem Laboratories, Ipca Laboratories and Torrent Pharma: Ajanta Pharmaceuticals' operating margin of 22.4% is the second highest of the four (Alkem Laboratories 17.8%, Ipca Laboratories 16.2%, Torrent Pharma 24.6%; peer average 19.5%); its return on equity of 25.4% is the second highest of the four (Alkem Laboratories 17.8%, Ipca Laboratories 15.2%, Torrent Pharma 27.1%; peer average 20.0%); its revenue growth over three years of 13.4% a year is the second highest of the four (Alkem Laboratories 8.3% a year, Ipca Laboratories 15.6% a year, Torrent Pharma 13.3% a year; peer average 12.4% a year).

Ajanta Pharmaceuticals vs Alkem Laboratories: how do they compare?

In FY26, Ajanta Pharmaceuticals earned net profit attributable to shareholders of ₹1,056 crore on revenue of ₹5,453 crore, against ₹2,302 crore on ₹14,712 crore for Alkem Laboratories. Ajanta Pharmaceuticals' operating margin was 22.4% (Alkem Laboratories 17.8%) and its return on equity 25.4% (Alkem Laboratories 17.8%). At the 29 October 2026 close, Ajanta Pharmaceuticals' market capitalisation was ₹43,367 crore against ₹60,719 crore for Alkem Laboratories, and its PE ratio on FY26 profit 41.1 against 26.4.

Where do these Ajanta Pharmaceuticals figures come from?

From Ajanta Pharmaceuticals' own consolidated results, balance sheets and shareholding patterns filed with NSE, and NSE prices (the latest used here: the 29 October 2026 close). Ratios are calculated by Alphave from those filings as each answer describes.

Consolidated figures from the company's filings with NSE; prices are NSE closing prices.